CBS 2019
CBSMD教育中心
English

动脉粥样硬化性心血管疾病预防

科研文章

荐读文献

The Use of Sex-Specific Factors in the Assessment of Women’s Cardiovascular Risk Simple Electrocardiographic Measures Improve Sudden Arrhythmic Death Prediction in Coronary Disease Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus From Detecting the Vulnerable Plaque to Managing the Vulnerable Patient From Focal Lipid Storage to Systemic Inflammation Coronary calcification in the diagnosis of coronary artery disease Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar Mediterranean Diet and the Association Between Air Pollution and Cardiovascular Disease Mortality Risk Atherosclerosis — An Inflammatory Disease

Review Article2021 Apr, 14 (7) 723–738

JOURNAL:JACC: Cardiovascular Interventions Article Link

Antithrombotic Management of Elderly Patients With Coronary Artery Disease

P Capranzano, DJ Angiolillo. Keywords: antithrombotic management; elderly; ischemic recurrence

ABSTRACT

Antithrombotic therapy represents the mainstay of treatment in patients with coronary artery disease (CAD), including elderly patients who are at increased risk for ischemic recurrences. However, the elderly population is also more vulnerable to bleeding complications. Numerous mechanisms, including abnormalities in the vasculature, thrombogenicity, comorbidities, and altered drug response, contribute to both increased thrombotic and bleeding risk. Age-related organ changes and drug-drug interactions secondary to polypharmacy lead to distinct pharmacokinetic and pharmacodynamic profiles of antithrombotic drugs. Overall these factors contribute to the risk-benefit profiles of antithrombotic therapies in elderly subjects and underscore the need for treatment regimens that can reduce bleeding while preserving efficacy. Given that the prevalence of CAD, as well as concomitant diseases with thromboembolic potential, such as atrial fibrillation, increases with age and that the elderly population is in continuous growth, understanding the safety and efficacy of different antithrombotic regimens is pivotal for patient-centered care. In the present overview the authors appraise the available data on the use of antithrombotic therapy in older patients with CAD to assist with the management of this high-risk population and define knowledge gaps that can set the basis for future research.